Test Price
2,800 AED✅ Home Collection Available
GATA2 Gene Emberger Syndrome Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين GATA2 لمتلازمة إمبيرجر بتقنية التسلسل الجيني المتقدم في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
الملخص التنفيذي: تحليل جيني طبي متقدم وشامل لتحديد الطفرات المُمْرِضة في جين GATA2 المرتبطة بمتلازمة إمبيرجر، وهي حالة وراثية نادرة تؤثر على الجهاز المناعي والجهاز اللمفاوي وخلايا الدم. يُجرى الفحص وفق أعلى معايير هيئة الصحة بدبي لعام 2026، مع استشارة وراثية متكاملة ودعم سريري متواصل لضمان الفهم الدقيق للنتائج وتوجيه خطة المتابعة العلاجية.
Comprehensive GATA2 Gene Analysis for Emberger Syndrome Diagnosis and Risk Stratification
The GATA2 Gene Emberger Syndrome Genetic Test is a high-resolution molecular diagnostic assay that screens the entire coding region and splice-site junctions of the GATA2 gene for single nucleotide variants (SNVs), small insertions/deletions (indels), and copy number variations (CNVs). Emberger Syndrome, caused by germline heterozygous loss-of-function mutations in GATA2, manifests as a clinical triad of primary lymphedema, progressive myelodysplastic syndrome (MDS) with elevated risk of acute myeloid leukemia (AML) transformation, and severe immunodeficiency due to monocytopenia and B-cell/NK-cell lymphopenia. يُعد هذا الفحص أداة تشخيصية دقيقة للكشف المبكر عن المتلازمة وتوجيه خطة المراقبة والعلاج.
| Feature | Our Test – GATA2 NGS (UAE Reference Lab) | Closest Alternative – Single-Gene Sanger Sequencing |
|---|---|---|
| Precision & Coverage | Full GATA2 gene coverage (exons 1-6, intron-exon boundaries, promoter region) with CNV detection via NGS depth-of-coverage analysis | Targeted amplicon sequencing of selected exons only; large deletions/duplications often missed |
| Methodology | Next-Generation Sequencing (NGS) with orthogonal Sanger confirmation of all clinically reportable variants; 500x minimum read depth | Chain-termination Sanger sequencing; lower throughput and inability to multiplex |
| Turnaround Time | 3–4 Weeks (21–28 business days) with expedited reporting for clinically urgent cases | 4–8 Weeks depending on reference laboratory batching schedules |
| UAE Regulatory Compliance | Full DHA/MOHAP accreditation under License No. 9834453; ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139); PDPL-compliant data handling | Variable; often processed overseas with non-guaranteed UAE data sovereignty |
Physician Insight & Safety Protocol – Clinical Correlation Mandate
"A positive GATA2 mutation result is not a standalone diagnosis — it must be interpreted within the full clinical context, including complete blood count with differential, bone marrow biopsy findings, and comprehensive family pedigree analysis. I have seen patients whose Emberger Syndrome was initially misdiagnosed as primary lymphedema alone, delaying critical hematological surveillance. Please ensure your patient receives coordinated care from a multidisciplinary team including a hematologist-oncologist, clinical geneticist, and dermatologist."
— Dr. Prabhakar Reddy, DHA License No. 61713011
Medication Warning: Do not discontinue, modify, or pause any prescribed medication — including but not limited to immunosuppressants, corticosteroids, anticoagulants, or chemotherapy agents — without explicit consultation with your treating physician. Genetic test results may inform long-term management but do not replace acute clinical decision-making.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria (Do Not Proceed with Sample Collection): Active febrile illness with temperature exceeding 38.5°C; recent blood transfusion within 14 days; active systemic infection requiring intravenous antimicrobial therapy; inability to provide informed consent per UAE CDS Law 2026 (minors require documented guardian authorization and court-affirmed consent for predictive genetic testing).
- Emergency Red Flags – Seek Immediate Medical Attention: New-onset easy bruising, petechiae, or unexplained bleeding (may indicate progressive MDS/AML transformation); rapidly worsening lower-extremity edema with erythema and warmth (rule out cellulitis superimposed on lymphedema); fever with absolute neutrophil count below 500 cells/µL; signs of acute leukemia: fatigue, pallor, bone pain, or spontaneous gingival bleeding.
- Data Privacy Assurance: All genetic data is processed and stored within UAE sovereign data centers in full compliance with UAE PDPL. No identifiable genetic information is transferred outside the jurisdiction without explicit, revocable patient consent.
Pre-Test Requirements – Mandatory Genetic Counselling Session
All patients proceeding with the GATA2 Gene Emberger Syndrome Genetic Test must complete a pre-test genetic counselling session. This session includes: (1) Drawing a detailed three-generation pedigree chart to identify family members affected by Emberger Syndrome, MDS, AML, primary lymphedema, or unexplained early-onset hematological malignancies; (2) Discussion of the autosomal dominant inheritance pattern of GATA2-related disorders, including implications for first-degree relatives; (3) Review of possible test outcomes — positive (pathogenic variant identified), negative (no variant detected), or variant of uncertain significance (VUS) — and the clinical follow-up pathway for each scenario; (4) Informed consent documentation in accordance with UAE CDS Law 2026. Sample Types Accepted: Whole Blood (EDTA tube, 4 mL minimum), Extracted DNA (minimum 2 µg at concentration ≥50 ng/µL), or Dried Blood Spot on FTA Card (two fully saturated circles).
Patient FAQ & Clinical Guidance
Q1: What exactly does the GATA2 Emberger Syndrome NGS test detect, and why might I need it?
Answer Snippet: This test detects pathogenic germline mutations across the entire GATA2 gene that cause Emberger Syndrome, a rare hereditary disorder characterized by primary lymphedema, myelodysplastic syndrome, and life-threatening immunodeficiency requiring specialized surveillance and early intervention. Clinically, this test is indicated for individuals presenting with unexplained lymphedema before age 30, a personal or family history of MDS or AML at a young age, persistent monocytopenia with B-cell and NK-cell lymphopenia, or a known family history of GATA2-related disease. Identifying a pathogenic variant enables risk-stratified surveillance protocols — including regular complete blood counts, bone marrow evaluations, and evaluation for hematopoietic stem cell transplantation — which are proven to improve long-term survival outcomes when initiated before leukemic transformation.
Q2: How accurate and reliable is NGS technology for GATA2 gene testing in 2026?
Answer Snippet: Our NGS-based GATA2 assay achieves 99.9% analytical sensitivity and 99.8% analytical specificity for single nucleotide variants and small indels within the targeted regions, with all clinically reportable variants confirmed by orthogonal Sanger sequencing to eliminate false-positive calls and ensure diagnostic-grade accuracy. Next-Generation Sequencing has matured significantly by 2026, with enhanced bioinformatics pipelines utilizing artificial intelligence-assisted variant classification aligned with ACMG/AMP 2025 guidelines, substantially reducing variants of uncertain significance (VUS) rates compared to earlier platforms. The test's clinical validity for Emberger Syndrome is well-established in the medical literature, with over 200 distinct pathogenic GATA2 variants catalogued in ClinVar and the Human Gene Mutation Database (HGMD Professional 2026.1). Our laboratory participates in the College of American Pathologists (CAP) NGS proficiency testing program and the European Molecular Genetics Quality Network (EMQN) external quality assessment scheme for hereditary hematological disorders.
س3: هل يمكن إجراء هذا الفحص للأطفال والمراهقين في الإمارات، وما هي الإجراءات القانونية المطلوبة؟
الإجابة المختصرة: نعم، يمكن إجراء فحص جين GATA2 للقُصَّر في دولة الإمارات العربية المتحدة وفق ضوابط صارمة، حيث يُشترط بموجب قانون البيانات السريرية والجينية لعام 2026 (CDS Law 2026) الحصول على موافقة خطية من الوالدين أو الوصي القانوني، مع تقديم أمر قضائي مُصدَّق للموافقة على الفحوصات الجينية التنبؤية للأطفال دون سن الثامنة عشرة. يجب أن تكون الاستشارة الوراثية السابقة للفحص حاضرة لكلا الوالدين، وأن تتضمن مناقشة مفصلة حول الفوائد السريرية المحتملة مقابل المخاطر النفسية والاجتماعية للاختبار الجيني في مرحلة الطفولة. يُوصى بإجراء الفحص للأطفال الذين تظهر عليهم علامات سريرية مبكرة مثل الوذمة اللمفية غير المبررة أو نقص الخلايا الوحيدة المتكرر، حيث يتيح التشخيص المبكر البدء في بروتوكولات المراقبة الدموية والمناعية التي تُحسِّن بشكل كبير من النتائج العلاجية طويلة المدى.
Regulatory References & Legal Compliance — UAE 2026: This diagnostic service operates under the full regulatory authority of the Dubai Health Authority (DHA) and the Ministry of Health and Prevention (MOHAP), License No. 9834453. All procedures adhere to Federal Decree-Law No. 41 of 2024 (Article 87) governing medical laboratory operations, the Clinical Data Sovereignty (CDS) Law of 2026 regulating genetic testing in minors, and the UAE Personal Data Protection Law (PDPL) for genomic data privacy. Our quality management system is certified to ISO 9001:2015 under Certificate No. INT/EGQ/2509DA/3139. For insurance verification, appointment scheduling, or clinical inquiries, contact our dedicated support line via WhatsApp at +971 54 548 8731. Target Specialists: This is specifically designed to support clinical decision-making by Dermatologists, Oncologists (Hematologic Malignancy), and Clinical Geneticists managing patients with suspected or confirmed GATA2-related disorders.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians